CSPC Pharmaceutical Group Limited announced that its first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of microsatellite-stable or proficient mismatch repair metastatic colorectal cancer (MSS/pMMR mCRC) in patients who have progressed after standard systemic therapies.

Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death in the United States. For patients with distant metastatic disease, the 5-year survival rate is approximately 17%, and median overall survival in the third-line setting for MSS/pMMR mCRC remains below 12 months, underscoring a significant unmet clinical need.

SYS6090 combines programmed cell death protein-1 (PD-1) blockade with interleukin-15 (IL-15) pathway activation through an asymmetric bispecific fusion structure. This design aims to selectively stimulate immune responses within “cold” MSS/pMMR tumors, potentially enhancing antitumor activity while limiting immune-related toxicity.

The FDA’s decision was supported by preclinical data and interim results from ongoing Phase 1 trials in China and the United States. Fast Track status provides CSPC Pharmaceutical with more frequent FDA interactions, priority review eligibility, and the potential for accelerated approval, expediting the therapy’s path to market.

The Board, chaired by Cai Dong Chen, emphasized that the designation highlights the drug’s potential to address a serious, life-threatening condition and marks a key milestone in the Group’s global oncology pipeline development.